Frederick G. Vogt

Frederick G. Vogt is a declared insider of Iovance Biotherapeutics, Inc. (chief executive), with filings sourced from SEC (Form 4). The record holds 26 filings, for trades running from 1 June 2022 to 8 September 2026.

The open-market record is one-sided, with 3 purchases worth €50k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants and 21 option exercises.

A typical purchase (the median) is worth €6,045. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The newest entry dates from 10 September 2026: an option exercise, in Iovance Biotherapeutics, Inc. The clock since the last published purchase (16 May 2025) now reads 520 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.